Premium
IC–P–127: Non–invasive early detection of beta–amyloid molecular pathology by quasi–elastic light scattering in vivo
Author(s) -
Goldstein Lee E.,
Moir Robert,
Lu Suqian,
Fu Ling,
Chadwick Oliver,
Arnett Ernest,
Ericcsson Maria,
Klunk William,
Mathis Chester,
Chylack Leo T.,
Clark John,
Tanzi Rudolph,
Moncaster Juliet
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.2333
Subject(s) - medicine , in vivo , cataracts , pathology , amyloid (mycology) , biomarker , genetically modified mouse , amyloid beta , disease , transgene , ophthalmology , biology , biochemistry , microbiology and biotechnology , gene
rescent signals with different lifetimes can be resolved in 3-dimensions. Screening of novel and existing near-infrared fluorophores resulted in several compounds with desirable properties as in vivo contrast agents. Using the new time-domain imaging algorithm, we will image transgenic mouse models of Alzheimer’s disease non-invasively to estimate plaque burden. Post-mortem confirmation of pathology will be used to correlate the in vivo results. Conclusions: These results, from simulations, to phantom measurements and in vivo imaging show that development of contrast agents and imaging approaches will allow sensitive imaging of amyloidbeta deposition in living APP mice with 3-dimensional information. This approach will accelerate pre-clinical drug development in animal models, and would ultimately translate to clinical imaging. Supported by NIH: EB00768, RR14075.